{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01446614",
      "OrgStudyIdInfo": {
        "OrgStudyId": "HM-2011-10"
      },
      "Organization": {
        "OrgFullName": "Guangzhou General Hospital of Guangzhou Military Command",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease",
      "OfficialTitle": "PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease."
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2011",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2014",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 4, 2011",
      "StudyFirstSubmitQCDate": "October 4, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 5, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 4, 2011",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 5, 2011",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "LeadSponsor": {
        "LeadSponsorName": "Guangzhou General Hospital of Guangzhou Military Command",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The study is a phase I/II trial designed to establish the safety and efficacy of intravenous administration of autologous bone marrow derived mesenchymal stem cells to patients with Parkinson's disease.",
      "DetailedDescription": "Parkinson's disease (PD) is a common progressive neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra. A combination of genetic and environmental factors is likely to be important in producing abnormal protein aggregation within select groups of neurones, leading to cell dysfunction and then death. A large number of agents together with surgical interventions are now available to treat early and late complications of PD, but they are suffer from two main drawbacks: side effects and loss of efficacy with disease progression.\n\nBone marrow (BM) derived mesenchymal stem cells (MSCs) an differentiate under certain circumstances into cells from various neuronal and glial type lineages; they also exert immunomodulatory effects. PD-derived MSCs are similar to normal MSCs in phenotype, morphology, and multidifferentiation capacity. Moreover, PD-derived MSCs are capable of differentiating into neurons in a specific medium with up to 30% having the characteristics of dopamine cells. These findings indicate that MSCs derived from PD patients' bone marrow may be a promising cell type for cellular therapy.\n\nBM-MSCs cultured with a cocktail of growth factors (containing FGF and BDNF) differentiate into neuronal/glial lineage cells with a predominance of cells expressing astrocytes' markers. They were effective in suppression of chronic EAE in mice and induced neuroprotection, preserving most of the axons in the CNS of successfully-treated animals. Histopathological studies revealed that MSCs could efficiently migrate into the CNS inflamed tissue (both when administered intravenously and intraventricularly) and differentiated into cells expressing neural-glial lineage markers. Such an approach may provide a feasible and practical way for PD."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Parkinson's Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: bone marrow derived mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "bone marrow derived mesenchymal stem cells",
            "InterventionDescription": "Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Mesenchymal Stem Cells",
                "Multipotent Mesenchymal Stem Cells",
                "Multipotent Mesenchymal Stromal Cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of participants with adverse events",
            "PrimaryOutcomeTimeFrame": "1 month after transplantation"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Effect assessment",
            "SecondaryOutcomeDescription": "Assessed by Unified Parkinson's Disease Rating Scale (UPDRS).",
            "SecondaryOutcomeTimeFrame": "1 month after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Effect assessment",
            "SecondaryOutcomeDescription": "Assessed by UPDRS",
            "SecondaryOutcomeTimeFrame": "3 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Effect assessment",
            "SecondaryOutcomeDescription": "Assessed by UPDRS",
            "SecondaryOutcomeTimeFrame": "6 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Effect assessment",
            "SecondaryOutcomeDescription": "Assessed by UPDRS",
            "SecondaryOutcomeTimeFrame": "12 months after transplantation"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatient with current diagnosis of idiopathic Parkinson's disease.\nAge 30 to 65.\nExperiencing motor complications despite optimized levodopa treatment.\nPD of Stage 2，2.5，3 or 4 of Hoehn-Yahr staging.\nTime between diagnosis and enrollment greater than 2 years.\nNo significant cognitive impairment. MMSE > 24.\nAbility to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nPatients may not be receiving any other investigational agents within 4 weeks of study entry.\nHistory of allergic reactions attributed to compounds of similar biologic composition to mesenchymal stem cells.\nPrimary hematologic diseases.\nPatients undergo intracranial surgeries or implantation of a device for Parkinson's disease.\nPsychiatric, addictive or any other disorder that compromises ability to give a truly informed consent and perform all study assessments.\nAtypical or secondary parkinsonism.\nMalignancy within the last 5 years.\nAny other serious medical illness that might preclude safe participation in the study.\nPregnant or breastfeeding women.\nHIV-positive patients.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "30 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Yang Xiao, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-20-36653562",
            "CentralContactEMail": "jdxiao111@163.com"
          },
          {
            "CentralContactName": "Li Li, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-20-36653562",
            "CentralContactEMail": "Lily17155@yahoo.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yang Xiao, MD",
            "OverallOfficialAffiliation": "Guangzhou General Hospital of Guangzhou Military Command",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Guangzhou General Hospital of Guangzhou Military Command",
            "LocationStatus": "Recruiting",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationZip": "510010",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Yang Xiao, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-20-36653562",
                  "LocationContactEMail": "jdxiao111@163.com"
                },
                {
                  "LocationContactName": "Li Li, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-20-36654678",
                  "LocationContactEMail": "Lily17155@yahoo.com"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "18040857",
            "ReferenceType": "background",
            "ReferenceCitation": "Wang Y, Chen S, Yang D, Le WD. Stem cell transplantation: a promising therapy for Parkinson's disease. J Neuroimmune Pharmacol. 2007 Sep;2(3):243-50. Epub 2007 May 9. Review."
          },
          {
            "ReferencePMID": "17610906",
            "ReferenceType": "background",
            "ReferenceCitation": "Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci. 2008 Feb 15;265(1-2):131-5. Epub 2007 Jul 3. Review."
          },
          {
            "ReferencePMID": "20129484",
            "ReferenceType": "background",
            "ReferenceCitation": "Schwarz J, Storch A. Transplantation in Parkinson's disease: will mesenchymal stem cells help to reenter the clinical arena? Transl Res. 2010 Feb;155(2):55-6. doi: 10.1016/j.trsl.2009.08.008. Epub 2009 Sep 19."
          },
          {
            "ReferencePMID": "20544825",
            "ReferenceType": "background",
            "ReferenceCitation": "Glavaski-Joksimovic A, Virag T, Mangatu TA, McGrogan M, Wang XS, Bohn MC. Glial cell line-derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease. J Neurosci Res. 2010 Sep;88(12):2669-81. doi: 10.1002/jnr.22435."
          },
          {
            "ReferencePMID": "20542127",
            "ReferenceType": "background",
            "ReferenceCitation": "Somoza R, Juri C, Baes M, Wyneken U, Rubio FJ. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease. Biol Blood Marrow Transplant. 2010 Nov;16(11):1530-40. doi: 10.1016/j.bbmt.2010.06.006. Epub 2010 Jun 10."
          },
          {
            "ReferencePMID": "19465139",
            "ReferenceType": "background",
            "ReferenceCitation": "Shetty P, Ravindran G, Sarang S, Thakur AM, Rao HS, Viswanathan C. Clinical grade mesenchymal stem cells transdifferentiated under xenofree conditions alleviates motor deficiencies in a rat model of Parkinson's disease. Cell Biol Int. 2009 Aug;33(8):830-8. doi: 10.1016/j.cellbi.2009.05.002. Epub 2009 May 22."
          },
          {
            "ReferencePMID": "18401666",
            "ReferenceType": "background",
            "ReferenceCitation": "Zhang Z, Wang X, Wang S. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In Vitro Cell Dev Biol Anim. 2008 May-Jun;44(5-6):169-77. doi: 10.1007/s11626-008-9093-1. Epub 2008 Apr 10."
          },
          {
            "ReferencePMID": "18665911",
            "ReferenceType": "background",
            "ReferenceCitation": "Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem. 2008 Oct;107(1):141-51. doi: 10.1111/j.1471-4159.2008.05589.x. Epub 2008 Jul 28."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010300",
            "ConditionMeshTerm": "Parkinson Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000020734",
            "ConditionAncestorTerm": "Parkinsonian Disorders"
          },
          {
            "ConditionAncestorId": "D000001480",
            "ConditionAncestorTerm": "Basal Ganglia Diseases"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009069",
            "ConditionAncestorTerm": "Movement Disorders"
          },
          {
            "ConditionAncestorId": "D000080874",
            "ConditionAncestorTerm": "Synucleinopathies"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12365",
            "ConditionBrowseLeafName": "Parkinson Disease",
            "ConditionBrowseLeafAsFound": "Parkinson's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21647",
            "ConditionBrowseLeafName": "Parkinsonian Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24756",
            "ConditionBrowseLeafName": "Ganglion Cysts",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15510",
            "ConditionBrowseLeafName": "Synovial Cyst",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3926",
            "ConditionBrowseLeafName": "Basal Ganglia Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11181",
            "ConditionBrowseLeafName": "Movement Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2217",
            "ConditionBrowseLeafName": "Synucleinopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          }
        ]
      }
    }
  }
}